Quick Answer
REGENEREX PHARMA, INC. reported Net Income Loss of -$2.53 million for the year ending 2025.
- REGENEREX PHARMA, INC. showed an increase of +28.7% in Net Income Loss from 2024 to 2025.
- This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2009 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $9.1 thousand | Q2 2011: $1.9 thousand | Q1 2012: $144.4 thousand | Q2 2012: -$8.2 thousand | Q3 2012: -$14.4 thousand | Q1 2013: -$244.4 thousand | Q2 2013: -$248.1 thousand | Q3 2013: -$248.3 thousand | Q1 2014: -$171.7 thousand | Q2 2014: $1.14 million | Q3 2014: -$59.1 thousand | Q1 2016: -$21.00 | Q4 2016: -$2.2 thousand | Q1 2017: -$8.1 thousand | Q2 2017: -$17.1 thousand | Q3 2017: -$8.1 thousand | Q4 2017: -$10.4 thousand | Q2 2018: -$18.6 thousand | Q3 2018: -$4.8 thousand | Q4 2018: -$53.7 thousand | Q2 2019: -$32.3 thousand | Q3 2019: -$18.5 thousand | Q4 2019: -$20.6 thousand | Q2 2020: -$9.8 thousand | Q3 2020: -$25.8 thousand | Q4 2020: -$33.7 thousand | Q2 2021: -$34.0 thousand | Q3 2021: -$33.8 thousand | Q4 2021: -$79.4 thousand | Q2 2022: -$23.2 thousand | Q3 2022: -$18.4 thousand | Q4 2022: -$49.4 thousand | Q2 2023: -$185.6 thousand | Q3 2023: -$2.80 million | Q4 2023: -$264.0 thousand | Q2 2024: -$272.6 thousand | Q3 2024: -$529.6 thousand | Q4 2024: -$314.5 thousand | Q2 2025: -$663.6 thousand | Q3 2025: -$814.0 thousand.
- Over the full 15 years of available data (2009 to 2025), REGENEREX PHARMA, INC.'s Net Income Loss has declined by 39,453.0%.
- Historical annual values: Fiscal year 2025: -$2.53 million | Fiscal year 2024: -$3.54 million | Fiscal year 2023: -$137.3 thousand | Fiscal year 2022: -$195.6 thousand | Fiscal year 2021: -$353.8 thousand | Fiscal year 2020: $111.6 thousand | Fiscal year 2019: -$93.6 thousand | Fiscal year 2018: -$49.7 thousand | Fiscal year 2017: -$2.6 thousand | Fiscal year 2014: $859.8 thousand | Fiscal year 2013: -$995.5 thousand | Fiscal year 2012: -$659.7 thousand | Fiscal year 2011: -$212.1 thousand | Fiscal year 2010: -$27.4 thousand | Fiscal year 2009: -$6.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: